简介:摘要:目的;评价阿利沙坦酯在临床环境中对轻、中度高血压和尿酸的影响,方法;2021年9月至2023年12月,在全国44个研究中心,轻、中度高血压患者每天服用240毫克阿利沙坦酯,并在治疗4周后评估其血压(收缩率、舒张压为<140、<90 mmHg,1 mmHg=0.133 kPa)不符合1:1随机抽取240毫克+1.5毫克阿利沙坦酯、吲达帕胺缓释A+D组,A+C组5毫克5 mg阿利沙坦酯片+苯磺酸氨氯地平8周,比较不同组血压和尿酸水平的变化。结果;486例高血压患者及尿酸血症,其中326例用单药治疗,A+D、A+C组83、77例,年龄、体质、基础血压、尿酸分别是52.81±11.27、25.84±2.61、149.66±10.28)/(92.85±8.26)mmHg、(459.41±72.76)μmol/L,12周治疗后,总体血压73.20%达标率。不达标单药及达标血压率A+D、A+C分别是55.13、49.32%,两组间差异无统计学意义。共有155(34.14%)恢复正常血尿酸,其中114(34.97%)单药组,A+D、A+C组是10、31例分别是12.0、40.26%,治疗后A+D组血尿酸468.62比497.72μmol/L,P=0.0167)增高,A+C 477.52比432.52μmol/L,P=0.0003)降低血尿酸,二者的差异具有统计学意义,结论:是以阿利沙坦酯为基础的高血压患者能够有效地控制血压,从而降低尿酸水平,钙拮抗剂联合应用更佳效果。
简介:摘要:目的 对比观察在对产后出血进行治疗的过程中,应用卡前列甲酯栓与缩宫素的效果差异,并探讨护理对策。方法 整理本院患者病历,将2020年8月-2021年8月时间段内接受治疗的产后出血患者资料抽取68份进行分析,患者随机均分2组各34例,参照组为缩宫素治疗患者,研究组为卡前列甲酯栓与缩宫素联合治疗患者,对比不同方案下患者治疗的差异。结果 研究组患者均出血量更低、有效性更高,对比有统计差异(P<0.05)。结论 在对产后出血进行治疗的过程中,应用卡前列甲酯栓与缩宫素联合治疗能够获得较高的有效性,辅以优质护理措施,能够进一步保证患者的安全性。
简介: 【摘 要】目的:观察单硝酸异山梨酯注射液对心肌梗死后并发症的临床疗效。方法:将 82例患者随机分为治疗组与对照组,每组 41例,治疗组使用单硝酸异山梨酯注射液 20mg混入 5%葡萄糖液 250ml中,静脉滴注,一日一次,连续使用 15天。对照组使用参麦注射液 60ml 混入 5%葡萄糖注射液 250ml中,静脉滴注,一日一次,并口服硝酸异山梨酯片 10mg,一日三次。结果:两组中,治疗组 41例,病死率为 4.8%;对照组 41例,病死率 12.2%。治疗组 41例,心绞痛发生率为 8%,心律失常发生率 5%;对照组 41例,心绞痛发生率为 39%。治疗组治疗效果明显高于对照组。结论:单硝酸异山梨酯注射液,能够有效的防治心肌梗死后并发症,防治冠心病心绞痛、心律失常等。具有起效快、疗效高、安全、不良反应少等特点,是一种安全有效的心血管药物,已成为治疗心血管疾病中的基本药物,在心肌梗塞后并发症中的常规用药。 【关键词】单硝酸异山梨酯注射液;心肌梗死;并发症;疗效 [Abstract] Objective: To observe the clinical effect of Isosorbide Mononitrate Injection on complications after myocardial infarction. Methods: 82 patients were randomly divided into treatment group and control group, 41 cases in each group. The treatment group was given Isosorbide Mononitrate Injection 20mg mixed with 250ml 5% glucose solution, intravenous drip, once a day, for 15 consecutive days. The control group was given Shenmai injection 60ml mixed with 250ml 5% glucose injection, intravenous drip, once a day, and oral isosorbide nitrate tablets 10mg, three times a day. Results: in the two groups, 41 cases in the treatment group, the mortality rate was 4.8%; 41 cases in the control group, the mortality rate was 12.2%. The incidence of angina pectoris and arrhythmia was 8% and 5% in the treatment group and 39% in the control group. The treatment effect of the treatment group was significantly higher than that of the control group. Conclusion: Isosorbide Mononitrate Injection can effectively prevent and treat the complications after myocardial infarction, coronary heart disease, angina pectoris and arrhythmia. It is a safe and effective cardiovascular drug. It has become the basic drug in the treatment of cardiovascular diseases and the conventional medication in the complications after myocardial infarction.
简介: 【摘 要】目的:分析胃肠镜检查术应用依托咪酯复合丙泊酚静脉麻醉的效果。方法:本次研究对象为本院在 2018年 7月 -2019年 7月间接受胃肠镜检查的患者,共 90例,根据住院顺序等分成 A组和 B组, A组实施依托咪酯麻醉, B组实施依托咪酯联合丙泊酚麻醉,对 2组患者体动、肌痉挛及检查时间、清醒时间、术中依托咪酯用量进行比较。结果: B组体动、肌痉挛的发生率低于 A组 ;检查与清醒时间相比, 2组无差异( P>0.05),依托咪酯用量相比, B组明显低于 A组( P<0.05)。结论:胃肠镜检查术中运用依托咪酯复合丙泊酚静脉麻醉,有着显著安全性,可以使体动、肌痉挛等不良反应的发生率有效减少,减少依托咪酯的用量,从而确保手术的顺利开展。 【关键词】依托咪酯 ;丙泊酚 ;麻醉 ;胃肠镜检查术 ;分析 Objective: to analyze the effect of intravenous anesthesia with etomidate combined with propofol in gastroenteroscopy. Methods: 90 patients who underwent gastroenteroscopy in our hospital from July 2018 to July 2019 were divided into group A and group B according to the order of hospitalization. Group A was given etomidate anesthesia, and group B was given etomidate combined with propofol anesthesia. The body movement, muscle spasm, examination time, awake time and intraoperative etomidate dosage were compared between the two groups. Results: the incidence of body movement and muscle spasm in group B was lower than that in group A; there was no difference between the two groups in terms of examination and awake time (P > 0.05), and the dosage of etomidate in group B was significantly lower than that in group A (P < 0.05). Conclusion: the application of etomidate combined with propofol intravenous anesthesia in gastroenteroscopy has significant safety, which can effectively reduce the incidence of body movement, muscle spasm and other adverse reactions, reduce the dosage of etomidate, so as to ensure the smooth operation.
简介: 【摘要】 目的 分析替诺福韦酯对核苷(酸)耐药的慢性乙型肝炎伴肝衰竭患者的临床效果。方法 60例对核苷(酸)耐药的慢性乙型肝炎伴肝衰竭患者, 随机分为对照组和观察组, 每组30例。对照组患者给予常规内科治疗, 观察组患者在对照组基础上给予富马酸替诺福韦二吡呋酯片治疗。观察比较两组患者乙肝病毒的脱氧核糖核酸(HBV-DNA)转阴率、治疗前后国际标准化比值(INR)、肝脏生化指标[总胆红素(TBIL)、总胆固醇(TC)、白蛋白(ALB)]、HBV-DNA载量及病死情况。結果 观察组患者HBV-DNA转阴率为50.00%(15/30), 高于对照组的13.33%(4/30), 差异具有统计学意义(P
简介:【摘要】目的 分析富马酸替诺福韦二吡呋酯联合扶正柔肝方在乙肝肝纤维化治疗中的应用效果。方法 选取2019年3月-2019年12月本院80例乙肝肝纤维化患者,随机分为对照组(富马酸替诺福韦二吡呋酯)与观察组(富马酸替诺福韦二吡呋酯联合扶正柔肝方),对比两组治疗效果。结果 TBIL、ALB、ALT、AST、HA、LN、PC-Ⅲ、Ⅳ-C方面,观察组较对照组优(P